JAPMA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levy, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levy, L. A.

Journal of the American Podiatric Medical Association, Vol 87, Issue 12 546-550, Copyright © 1997 by American Podiatric Medical Association

JOURNAL ARTICLE

Epidemiology of onychomycosis in special-risk populations

LA Levy
California College of Podiatric Medicine, San Francisco 94115-4000, USA.

A person's susceptibility to onychomycosis and the course of the disease once the nails are infected are functions of the interaction of the fungal agent, the host, and environmental factors. The disease is reported to have an overall prevalence of 2% to 13%, but the prevalence is much higher in certain populations, such as older people and those with immunosuppressive conditions. Although onychomycosis may be merely a nuisance and an embarrassment for healthy individuals, some morbidity is seen with all population groups, but especially high-risk patients: diabetics, patients infected with human immunodeficiency virus (HIV), patients with acquired immunodeficiency syndrome (AIDS), and patients with other types of immunosuppression (eg, transplant recipients and patients on long-term corticosteroid therapy). Whether the increased prevalence of onychomycosis in the elderly (up to 30% by age 60) is related to changes in immune function is not known.


This article has been cited by other articles:


Home page
 J. Am. Podiatr. Med. Assoc.Home page
M. A. Brenner, L. B. Harkless, R. W. Mendicino, and J. C. Page
Ciclopirox 8% Nail Lacquer Topical Solution for the Treatment of Onychomycosis in Patients with Diabetes: A Multicenter, Open-Label Study
J Am Podiatr Med Assoc, May 1, 2007; 97(3): 195 - 202.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
J. M. Binstock
Molecular Biology Techniques for Identifying Dermatophytes and Their Possible Use in Diagnosing Onychomycosis in Human Toenail: A Review
J Am Podiatr Med Assoc, March 1, 2007; 97(2): 134 - 144.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
J. A. Winston and J. L. Miller
Treatment of Onychomycosis in Diabetic Patients
Clin. Diabetes, October 1, 2006; 24(4): 160 - 166.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
S. C. Frank and H. L. Freer
Onychauxic Dystrophic Toenails Requiring Debridement in Medicare Patients: Prevalence and Anatomical Distribution
J Am Podiatr Med Assoc, September 1, 2003; 93(5): 388 - 391.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
M. B. Jennings and M. G. Rinaldi
Confirmation of Dermatophytes in Nail Specimens Using In-Office Dermatophyte Test Medium Cultures: Insights from a Multispecialty Survey
J Am Podiatr Med Assoc, May 1, 2003; 93(3): 195 - 202.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
P. Rich, L. B. Harkless, and E. S. Atillasoy
Dermatophyte Test Medium Culture for Evaluating Toenail Infections in Patients With Diabetes
Diabetes Care, May 1, 2003; 26(5): 1480 - 1484.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Podiatric Medical Association.